Last reviewed · How we verify
opioid dose escalation
opioid dose escalation is a Small molecule drug developed by VA Office of Research and Development. It is currently FDA-approved for Chronic pain management in opioid-tolerant patients, Cancer pain, Severe chronic non-cancer pain. Also known as: No other names.
Opioid dose escalation is a clinical practice of incrementally increasing opioid medication doses to maintain analgesic efficacy in patients with chronic pain.
Opioid dose escalation is a clinical practice of incrementally increasing opioid medication doses to maintain analgesic efficacy in patients with chronic pain. Used for Chronic pain management in opioid-tolerant patients, Cancer pain, Severe chronic non-cancer pain.
At a glance
| Generic name | opioid dose escalation |
|---|---|
| Also known as | No other names |
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
This is a dosing strategy rather than a novel drug entity. It involves titrating opioid doses upward over time to overcome tolerance or achieve adequate pain control in opioid-tolerant patients. The mechanism relies on the existing pharmacology of opioid receptor agonism, with escalation used to maintain therapeutic effect as patients develop tolerance to the drug.
Approved indications
- Chronic pain management in opioid-tolerant patients
- Cancer pain
- Severe chronic non-cancer pain
Common side effects
- Respiratory depression
- Constipation
- Sedation
- Nausea
- Overdose risk
Key clinical trials
- Extended-release Buprenorphine as a Novel Low-dose Induction Strategy (PHASE2)
- Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy (PHASE1)
- Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia (PHASE4)
- Opioid-free Analgesia in Intensive Care Unit (PHASE4)
- Buprenorphine-Fentanyl Interaction Study (PHASE1)
- Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder (PHASE1)
- Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) (PHASE1)
- Evaluation of Oral PF614 Relative to OxyContin (PF614-102) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- opioid dose escalation CI brief — competitive landscape report
- opioid dose escalation updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI
Frequently asked questions about opioid dose escalation
What is opioid dose escalation?
How does opioid dose escalation work?
What is opioid dose escalation used for?
Who makes opioid dose escalation?
Is opioid dose escalation also known as anything else?
What development phase is opioid dose escalation in?
What are the side effects of opioid dose escalation?
Related
- Manufacturer: VA Office of Research and Development — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Chronic pain management in opioid-tolerant patients
- Indication: Drugs for Cancer pain
- Indication: Drugs for Severe chronic non-cancer pain
- Also known as: No other names
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing